enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
7.76
+0.16 (2.11%)
At close: Apr 15, 2026, 4:00 PM EDT
7.76
0.00 (0.00%)
After-hours: Apr 15, 2026, 4:10 PM EDT
enGene Therapeutics Employees
As of October 31, 2025, enGene Therapeutics had 82 total employees, including 81 full-time and 1 part-time employees. The number of employees increased by 25 or 43.86% compared to the previous year.
Employees
82
Change (1Y)
25
Growth (1Y)
43.86%
Revenue / Employee
n/a
Profits / Employee
-$1,493,146
Market Cap
519.84M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 82 | 25 | 43.86% | 81 | 1 |
| Oct 31, 2024 | 57 | 24 | 72.73% | 56 | 1 |
| Oct 31, 2023 | 33 | - | - | 31 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| ADC Therapeutics | 193 |
| Entrada Therapeutics | 152 |
| Absci | 140 |
| Invivyd | 122 |
| Verastem | 102 |
| Assembly Biosciences | 73 |
| Larimar Therapeutics | 71 |
| AgomAb Therapeutics NV | 58 |
ENGN News
- 8 days ago - enGene Announces Name Change to enGene Therapeutics Inc. - Business Wire
- 5 weeks ago - enGene Reports First Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 7 weeks ago - enGene to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire
- 3 months ago - enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc. - Business Wire
- 4 months ago - enGene Reports Full Year 2025 Financial Results and Provides Business Update - Business Wire
- 4 months ago - enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness - Business Wire
- 5 months ago - enGene to Present at the Piper Sandler 37th Annual Healthcare Conference - Business Wire